C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis-Reference-Cited by-同舟云学术

C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis

Published:2015-02 Issue:2 Volume:62 Page:354-362
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Liu Jianjun,Tan Yulong,Zhang Jinyu,Zou Liyun,Deng Guohong,Xu Xueqing,Wang Feng,Ma Zhengwei,Zhang Jue,Zhao Tingting,Liu Yunlai,Li Yongsheng,Zhu Bo,Guo Bo

Publisher

Elsevier BV

Subject

Hepatology

Reference54 articles.

1. Acute liver failure;Lee;N Engl J Med,1993

2. Acute liver failure;Bernal;Lancet,2010

3. Fulminant viral hepatitis: molecular and cellular basis, and clinical implications;Liu;Expert Rev Mol Med,2001

4. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis;Marsden;J Clin Invest,2003

5. 16, 16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection;Abecassis;J Clin Invest,1987

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The changes of coagulation profiles in Kawasaki disease and its associations with clinical classification, intravenous immunoglobulin responsiveness and coronary artery involvement;Clinical and Experimental Medicine;2024-08-06

2. FGL1 and FGL2: emerging regulators of liver health and disease;Biomarker Research;2024-05-31

3. Factor H’s Control of Complement Activation Emerges as a Significant and Promising Therapeutic Target for Alzheimer’s Disease Treatment;International Journal of Molecular Sciences;2024-02-14

4. FGL2 as a predictive biomarker for prognosis and immunotherapy in bladder cancer;International Journal of Medical Sciences;2024

5. Sinusoidal cell interactions—From soluble factors to exosomes;Sinusoidal Cells in Liver Diseases;2024